These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38787254)

  • 21. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.
    Elkhalifa D; Siddique AB; Qusa M; Cyprian FS; El Sayed K; Alali F; Al Moustafa AE; Khalil A
    Eur J Med Chem; 2020 Feb; 187():111954. PubMed ID: 31838326
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Liu H; Sun H; Zhang B; Liu S; Deng S; Weng Z; Zuo B; Yang J; He Y
    Breast Cancer; 2020 May; 27(3):372-380. PubMed ID: 31781983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
    Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV
    J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Establishment of a bioluminescent MDA-MB-231 cell line for human triple-negative breast cancer research.
    Wang K; Xie S; Ren Y; Xia H; Zhang X; He J
    Oncol Rep; 2012 Jun; 27(6):1981-9. PubMed ID: 22446691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2
    Ly S; Anand V; El-Dana F; Nguyen K; Cai Y; Cai S; Piwnica-Worms H; Tripathy D; Sahin AA; Andreeff M; Battula VL
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential susceptibility of human cancer cell lines to wild-type tanapoxvirus infection.
    Lee HL; Essani K
    Open Virol J; 2010 Apr; 4():1-6. PubMed ID: 20461227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.
    Brito Baleeiro R; Liu P; Chard Dunmall LS; Di Gioia C; Nagano A; Cutmore L; Wang J; Chelala C; Nyambura LW; Walden P; Lemoine N; Wang Y
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In Vivo Selection of Intermediately- and Highly-Malignant Variants of Triple-negative Breast Cancer in Orthotopic Nude Mouse Models.
    Yano S; Takehara K; Kishimoto H; Tazawa H; Urata Y; Kagawa S; Bouvet M; Fujiwara T; Hoffman RM
    Anticancer Res; 2016 Dec; 36(12):6273-6277. PubMed ID: 27919946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
    Desroys du Roure P; Lajoie L; Mallavialle A; Alcaraz LB; Mansouri H; Fenou L; Garambois V; Rubio L; David T; Coenon L; Boissière-Michot F; Chateau MC; Ngo G; Jarlier M; Villalba M; Martineau P; Laurent-Matha V; Roger P; Guiu S; Chardès T; Gros L; Liaudet-Coopman E
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38290768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Triple-Negative Breast Cancer: Basic Biology and Immuno-Oncolytic Viruses.
    Monaco ML; Idris OA; Essani K
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccinia virus GLV-1h153 is effective in treating and preventing metastatic triple-negative breast cancer.
    Gholami S; Chen CH; Lou E; De Brot M; Fujisawa S; Chen NG; Szalay AA; Fong Y
    Ann Surg; 2012 Sep; 256(3):437-45. PubMed ID: 22868370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heterologous prime-boost cellular vaccination induces potent antitumor immunity against triple negative breast cancer.
    Niavarani SR; St-Cyr G; Daniel L; Lawson C; Giguère H; Alkayyal AA; Tai LH
    Front Immunol; 2023; 14():1098344. PubMed ID: 36860852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adeno-associated virus type 2 infection of nude mouse human breast cancer xenograft induces necrotic death and inhibits tumor growth.
    Alam S; Bowser BS; Israr M; Conway MJ; Meyers C
    Cancer Biol Ther; 2014 Aug; 15(8):1013-28. PubMed ID: 24834917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
    Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
    Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Establishment of a bioluminescent MDA-MB-231 cell line for in vivo imaging of human triple-negative breast cancer xenograft].
    Wang K; Xie SM; He JJ; Ren Y; Xia HB; Zhang XW
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Nov; 31(11):1812-8. PubMed ID: 22126756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer.
    Zhang D; Sun B; Zhao X; Ma Y; Ji R; Gu Q; Dong X; Li J; Liu F; Jia X; Leng X; Zhang C; Sun R; Chi J
    Mol Cancer; 2014 Sep; 13():207. PubMed ID: 25200065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases.
    Shin SU; Cho HM; Das R; Gil-Henn H; Ramakrishnan S; Al Bayati A; Carroll SF; Zhang Y; Sankar AP; Elledge C; Pimentel A; Blonska M; Rosenblatt JD
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer.
    Gao M; Wang T; Ji L; Bai S; Tian L; Song H
    Front Immunol; 2020; 11():366. PubMed ID: 32194569
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Kasten BB; Oliver PG; Kim H; Fan J; Ferrone S; Zinn KR; Buchsbaum DJ
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29561763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.